UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 4, 2006
Adeza Biomedical Corporation
(Exact name of registrant as specified in its charter)
000-20703
(Commission File Number)
| |
|
|
| Delaware
|
|
77-0054952 |
| (State or other jurisdiction of
|
|
(I.R.S. Employer Identification No.) |
| incorporation) |
|
|
1240 Elko Drive
Sunnyvale, California 94089
(Address of principal executive offices, with zip code)
(408) 745-0975
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
| |
o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
| |
o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
| |
o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
| |
| |
o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) |
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard;
Transfer of Listing.
(a) On August 4, 2006, Adeza Biomedical Corporation (the “Company”) received a letter from
Nasdaq informing the Company that, due to the resignation of Nancy D. Burrus from the Company’s
board of directors, the Company was no longer in compliance with the requirements for listing on
The Nasdaq Global Market under Marketplace Rule 4350(d)(2), which requires that the Company’s audit
committee have at least three independent directors. The letter also informed the Company that
under Marketplace Rule 4350(d)(4), the Company had until its next annual shareholders’ meeting to
remedy this non-compliance. On August 8, 2006, C. Gregory Vontz, an independent member of the
Company’s board of directors, was appointed to the Company’s audit committee. On August 8, 2006,
Nasdaq notified the Company that the appointment of Mr. Vontz to the audit committee restored the
Company’s compliance with Rule 4350(d)(2) and that the matter is now closed.